Search

Your search keyword '"Dancey J"' showing total 303 results
Start Over Author "Dancey J"
303 results on '"Dancey J"'

1. Targeted agents for the treatment of metastatic melanoma

Author

Monzon JG and Dancey J

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Jose G Monzon, Janet DanceyNCIC Clinical Trials Group, Kingston, Ontario, CanadaAbstract: In the last year, the armamentarium of melanoma therapeutics has radically changed. Recent discoveries in melanoma biology and immunology have led to novel therapeutics targeting known oncogenes and immunotherapeutic antibodies. Phase III clinical trials of these agents have reported measurable and meaningful benefits to patients with metastatic disease. In this article, we review recent findings and discuss their significance in melanoma therapy. As our understanding of melanoma biology grows, this initial therapeutic success may be enhanced through the use of molecular markers to select patients, and new targeted immunotherapies in sequential or combination drug regimens.Keywords: metastatic melanoma, ipilimumab, vemurafenib, antitumor

Published
2012

17. Quality of life as a prognostic indicator of survival: A pooled analysis of individual patient data from canadian cancer trials group clinical trials

Author

Ediebah, D.E., Quinten, C., Coens, C., Ringash, J., Dancey, J., Zikos, E., Gotay, C., Brundage, M., Tu, D.S., Flechtner, H.H., Greimel, E., Reeve, B.B., Taphoorn, M., Reijneveld, J., Dirven, L., Bottomley, A., Canadian Canc Trials Grp, European Org Res Treatment Canc, VU University medical center, Neurology, CCA - Cancer Treatment and quality of life, Graduate School, and CCA - Cancer Treatment and Quality of Life

Subjects
Adult, Male, Canada, Cancer Research, medicine.medical_specialty, Health Status, overall survival, cancer clinical trial, law.invention, 03 medical and health sciences, 0302 clinical medicine, Randomized controlled trial, Quality of life, law, Neoplasms, Internal medicine, medicine, Health Status Indicators, Humans, Multicenter Studies as Topic, 030212 general & internal medicine, prognostic factor, Aged, Randomized Controlled Trials as Topic, Performance status, Proportional hazards model, business.industry, Hazard ratio, Cancer, Middle Aged, Prognosis, medicine.disease, Survival Analysis, Confidence interval, humanities, health-related quality of life, Clinical trial, Clinical Trials, Phase III as Topic, Oncology, 030220 oncology & carcinogenesis, Quality of Life, Female, pooled analysis, business
Abstract

BACKGROUND: The aims of this study were to externally validate an established association between baseline health-related quality of life (HRQOL) scores and survival and to assess the added prognostic value of HRQOL with respect to demographic and clinical indicators. METHODS: Pooled data were analyzed from 17 randomized controlled trials opened by the Canadian Cancer Trials Group between 1991 and 2004; they included survival and baseline HRQOL data from 3606 patients with 8 different cancer sites. The models included sex, age (≤60 vs >60 years), World Health Organization performance status (0 or 1 vs 2-4), distant metastases (no vs yes), and 15 European Organization for Research and Treatment of Cancer (EORTC) Core Quality-of-Life Questionnaire (QLQ-C30) scales. Analyses were conducted with multivariate Cox proportional hazards models and were stratified by cancer site. Harrell's discrimination C-index was used to calculate the predictive accuracy of the model when HRQOL parameters were added to clinical and demographic variables. The added value of adding HRQOL scales to clinical and demographic variables was illustrated with Kaplan-Meier curves. RESULTS: In the stratified, multivariate model, HRQOL parameters—global health status (hazard ratio [HR], 0.97; 95% confidence interval [CI], 0.95-1.00; P

Published
2018

20. Management of Kidney Cancer: Canadian Kidney Cancer Forum Consensus Update 2011: Canadian Kidney Cancer Forum 2011

Author

Jewett, MAS, Finelli, A, Kollmannsberger, C, Wood, L, Legere, L, Basiuk, J, Canil, C, Heng, D, Reaume, N, Tanguay, S, Atkins, M, Bjarnason, G, Dancey, J, Evans, M, Fleshner, N, Haider, M, Kapoor, A, Uzzo, R, Maskens, D, Soulieres, D, Yousef, G, Basappa, N, Bendali, N, Black, P, Blais, N, Cagiannos, I, Care, M, Chow, R, Chung, H, Czaykowski, P, DeRosa, D, Durrant, K, Ellard, S, Farquharson, G, Filion-Brulotte, C, Gingerich, J, Godbout, L, Grant, R, Hamilton, W, Kassouf, W, Kurban, G, Lane, K, Lattouf, JB, Lau, D, Leveridge, M, McCarthy, J, Moore, R, North, S, O’Brien, P, Pituskin, E, Racine, P, Rendon, R, So, A, Sridhar, S, Stubbs, K, Su, Z, Taylor, L, Udall, T, Venner, P, Vogel, W, Yap, S, Yau, P, Cooper, M, Giroux, N, Miron, D, Mosher, D, Ross, K, and Willacy, J

Subjects
Consensus Statement
Published
2012

22. Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02

Author

Wen, P. Y., primary, Chang, S. M., additional, Lamborn, K. R., additional, Kuhn, J. G., additional, Norden, A. D., additional, Cloughesy, T. F., additional, Robins, H. I., additional, Lieberman, F. S., additional, Gilbert, M. R., additional, Mehta, M. P., additional, Drappatz, J., additional, Groves, M. D., additional, Santagata, S., additional, Ligon, A. H., additional, Yung, W. K. A., additional, Wright, J. J., additional, Dancey, J., additional, Aldape, K. D., additional, Prados, M. D., additional, and Ligon, K. L., additional

Published
2014
Full Text
View/download PDF

24. Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02

Author

Lee, E. Q., primary, Kuhn, J., additional, Lamborn, K. R., additional, Abrey, L., additional, DeAngelis, L. M., additional, Lieberman, F., additional, Robins, H. I., additional, Chang, S. M., additional, Yung, W. K. A., additional, Drappatz, J., additional, Mehta, M. P., additional, Levin, V. A., additional, Aldape, K., additional, Dancey, J. E., additional, Wright, J. J., additional, Prados, M. D., additional, Cloughesy, T. F., additional, Gilbert, M. R., additional, and Wen, P. Y., additional

Published
2012
Full Text
View/download PDF

25. Health-related quality-of-life studies of the National Cancer Institute of Canada Clinical Trials Group

Author

Osoba, D., Dancey, J., Benny Chung-Ying Zee, Myles, J., and Pater, J.

Subjects
Canada, Clinical Trials, Phase III as Topic, Neoplasms, Quality of Life, Humans
Abstract

Since 1989, the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) has been successful in implementing and completing health-related quality-of-life (HQL) assessments as part of phase III clinical trials. Compliance rates for completing HQL instruments remain high, with a minimal amount of missing data. It is believed that this success is attributable not only to the high degree of commitment to measuring HQL by clinical trials investigators, nurses, data managers, and central office administrative staff, but also to the educational process that was instituted after the development of a CTG policy for measuring HQL. From inception to May 1995, a total of 27 clinical trials with HQL assessment have been initiated or completed. In the majority of trials, the core HQL instrument is the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30). In addition to answering specific questions about HQL in these clinical trials, the trials provide the opportunity to do research into the measurement of HQL. Thus, current clinical trials include research questions about the appropriate timing of assessments, the reliability and validity of the QLQ-C30 and other instruments, the role of HQL data in assessing toxicity, and the significance of the results of HQL assessments. It is anticipated that this activity not only will be a rich source of information about the effects of cancer and its treatment on HQL but also will lead to improvements in measuring HQL in oncology.

Published
1996

31. Lessons learned from independent central review

Author

Ford, R., primary, Schwartz, L., additional, Dancey, J., additional, Dodd, L.E., additional, Eisenhauer, E.A., additional, Gwyther, S., additional, Rubinstein, L., additional, Sargent, D., additional, Shankar, L., additional, Therasse, P., additional, and Verweij, J., additional

Published
2009
Full Text
View/download PDF

32. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

Author

Eisenhauer, E.A., primary, Therasse, P., additional, Bogaerts, J., additional, Schwartz, L.H., additional, Sargent, D., additional, Ford, R., additional, Dancey, J., additional, Arbuck, S., additional, Gwyther, S., additional, Mooney, M., additional, Rubinstein, L., additional, Shankar, L., additional, Dodd, L., additional, Kaplan, R., additional, Lacombe, D., additional, and Verweij, J., additional

Published
2009
Full Text
View/download PDF

33. 32 INVITED New response evaluation criteria in solid tumors: revised RECIST guideline version 1.1

Author

Eisenhauer, E., primary, Therasse, P., additional, Bogaerts, J., additional, Schwartz, L., additional, Sargent, D., additional, Ford, R., additional, Dancey, J., additional, Arbuck, S., additional, Gwyther, S., additional, Mooney, M., additional, Rubenstein, L., additional, Shankar, L., additional, Kaplan, R., additional, Lacombe, D., additional, and Verweij, J., additional

Published
2008
Full Text
View/download PDF

41. A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas

Author

Duran, I, primary, Kortmansky, J, additional, Singh, D, additional, Hirte, H, additional, Kocha, W, additional, Goss, G, additional, Le, L, additional, Oza, A, additional, Nicklee, T, additional, Ho, J, additional, Birle, D, additional, Pond, G R, additional, Arboine, D, additional, Dancey, J, additional, Aviel-Ronen, S, additional, Tsao, M-S, additional, Hedley, D, additional, and Siu, L L, additional

Published
2006
Full Text
View/download PDF

48. 123 Discussion of toxicity and biomarkers in a phase i trial of gefitinib (IRESSATM) in combination with radiation or chemo-radiation for patients with locally advanced head and neck cancer (LAHNC)

Author

Raben, D., primary, Chen, C., additional, Kane, M., additional, Song, J., additional, Eckhardt, G., additional, Meyers, A., additional, McCoy, K., additional, Raben, A., additional, Quon, H., additional, Hu, K., additional, and Dancey, J., additional

Published
2006
Full Text
View/download PDF

49. Maturing Toxicity and Outcomes of a Phase I Trial of Concurrent, Daily Gefitinib and Radiation or Chemoradiation for Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck (LASCCHN)

Author

Raben, D., primary, Chen, C., additional, Eckhardt, G.S., additional, Kane, M., additional, Song, J.I., additional, Bemis, L., additional, Varella-Garcia, M., additional, Brualdi, L., additional, Raben, A., additional, Hu, K., additional, Quon, H., additional, and Dancey, J., additional

Published
2005
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results